Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results of the randomized GO-FORTH trial

Yoshiya Tanaka, Masayoshi Harigai, Tsutomu Takeuchi, Hisashi Yamanaka, Naoki Ishiguro, Kazuhiko Yamamoto, Nobuyuki Miyasaka, Takao Koike, Daniel Baker, Yutaka Ishii, Toru Yoshinari

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: To evaluate the safety and efficacy of golimumab + methotrexate (MTX) in Japanese patients with active rheumatoid arthritis (RA). Methods: Japanese patients with active RA despite MTX were randomized to placebo + MTX (Group 1, n = 88), golimumab 50 mg + MTX (Group 2, n = 86), or golimumab 100 mg + MTX (Group 3, n = 87). Patients with 

Original languageEnglish
Pages (from-to)1-10
Number of pages10
JournalModern Rheumatology
DOIs
Publication statusAccepted/In press - 2015 Dec 22

    Fingerprint

Keywords

  • Anti-tumor necrosis factor
  • Asian
  • Golimumab
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology

Cite this